Oncologists in United Arab Emirates, Saudi Arabia, Kuwait, Oman,
Bahrain, Qatar, and Lebanon will be empowered to make more informed
clinical decisions to personalize treatment and care for their patients
Partnership builds on international expansion of GPS Cancer which was
recently made available in Italy and Israel
CULVER CITY, Calif. & DUBAI, United Arab Emirates--(BUSINESS WIRE)--
NantHealth,
Inc., (Nasdaq: NH), a leading next-generation, evidence-based,
personalized healthcare company, today announced that it has entered
into an exclusive reseller agreement for GPS
Cancer advanced molecular analysis with Lunatus,
a company focused on linking international healthcare companies and
regional healthcare professionals in Arabian Gulf and Middle East
markets. The molecular tests will help guide the decisions made by
oncologists located in the Middle East regarding a patient’s treatment
strategy, including choice of standard chemotherapy.
"It is estimated that total healthcare spending in the Gulf Cooperation
Council (GCC) countries will reach $60 billion (US dollars) in 2025, up
from $12 billion (US dollars) today[1],” said Patrick
Soon-Shiong, MD, CEO of NantHealth. “As a key player in the field of
healthcare services and a pioneer in personalized medicine and molecular
testing in the Middle East, we’re excited to partner with Lunatus to
help relieve some of this financial burden by supplying community
oncologists with best-in-class tools that will help to make more
informed treatment decisions for cancer patients at the initial point of
care. This specific region is the only one in the world that sees so
much growth in demand for healthcare treatment and bringing GPS Cancer
to the communities is an opportunity to offer patients a new standard of
care.”
Since becoming commercially available in June
2016, GPS Cancer has established its global footprint in not only
the European market, but now in the Middle East. This expansion adds to
the growing set of payers, providers, and a Fortune 50 company that have
already committed to covering or using the comprehensive molecular
profile. Under the terms of the agreement, Lunatus will have exclusive
rights to distribute GPS Cancer to physicians in the Middle East,
including the following countries: United Arab Emirates, Saudi Arabia,
Kuwait, Oman, Bahrain, Qatar, and Lebanon. The test, which integrates
quantitative proteomics with whole genome (DNA) and transcriptome (RNA)
sequencing, is the only integrated comprehensive molecular test of its
type conducted in CLIA-certified and CAP-accredited laboratories. It
provides oncologists with a comprehensive molecular profile of a
patient’s cancer to inform personalized treatment strategies. As a
cornerstone of the Cancer
MoonShot 2020 program, GPS Cancer provides key insights based on the
unique biology of a patient’s tumor—from the DNA to the RNA to the
protein. This rich information helps doctors build more effective
treatment plans based on FDA-approved drugs and active clinical trials,
while enabling cancer researchers to design new clinical trials that
harness the potential of the immune system.
"As the GCC states are expected to see increases of cancer rates– around
150-200 percent increase by the year 2030 – our mission is to make a
positive impact on those diagnosed with cancer in the hopes of
dramatically reducing these devastating expectations of our region,”
said Dr. Lina Kouatly, President and CEO of Lunatus. “We have an
impressive track record of building brands for healthcare services and
products in the Middle East and through our broad network with
government and regulatory entities, local oncology communities,
hospitals, clinics and pathology labs, influencers, as well as research
communities, we are so pleased to be the first to offer our partners a
one-of-a-kind test that will ultimately help advance personalized cancer
care.”
Unlike other tests on the market, GPS Cancer sequences the whole genome
of 20,000+ genes and three billion base pairs and matches against the
patient’s normal DNA, providing oncologists with an expansive view of
alterations to inform personalized treatment strategies. GPS Cancer
extends from genomics to proteomics not only through analysis of RNA,
but also utilizes quantitative proteomics through mass spectrometry to
measure the amounts of clinically relevant proteins that are the targets
of or essential for various therapeutics. This clinically relevant
information helps oncologists to better understand how patients may
potentially respond to chemotherapies, targeted therapies and
immunotherapies.
About NantHealth, Inc.
NantHealth, Inc., a member of the
NantWorks ecosystem of companies, is a next-generation, evidence-based,
personalized healthcare company enabling improved patient outcomes and
more effective treatment decisions for critical illnesses. NantHealth’s
unique systems-based approach to personalized healthcare applies novel
diagnostics tailored to the specific molecular profiles of patient
tissues and integrates this molecular data in a clinical setting with
large-scale, real-time biometric signal and phenotypic data to track
patient outcomes and deliver precision medicine. For nearly a decade,
NantHealth has developed an adaptive learning system, CLINICS, which
includes its unique software, middleware and hardware systems
infrastructure that collects, indexes, analyzes and interprets billions
of molecular, clinical, operational and financial data points derived
from novel and traditional sources, continuously improves
decision-making and further optimizes our clinical pathways and decision
algorithms over time. For more information please visit www.nanthealth.com and
follow Dr. Soon-Shiong on Twitter @DrPatSoonShiong.
About GPS Cancer™
GPS Cancer™ is a comprehensive molecular
profile available through NantHealth. GPS Cancer integrates whole genome
(DNA) sequencing, whole transcriptome (RNA) sequencing, and quantitative
proteomics through mass spectrometry, providing oncologists with
unprecedented insight into the molecular signature of each patient’s
cancer to inform personalized treatment strategies. GPS Cancer profiling
is conducted in CLIA-certified and CAP-accredited laboratories, and is a
key enabler for Cancer MoonShot 2020, the world’s most comprehensive
cancer collaborative initiative seeking to accelerate the potential of
combination immunotherapy as the next generation standard of care in
cancer patients. For more information, visit www.gpscancer.com
and www.cancermoonshot2020.org.
About Lunatus
Since its inception in 2003, Lunatus has
established a successful track record in introducing, building and
developing profitable brands in the fields of pharmaceutical, RX & OTC,
aesthetic medicine & skin care, consumer health and medical equipment
for international healthcare companies in the Arabian Gulf and Middle
East markets. The Company’s mission is to provide value added marketing
and operational services tailored to the versatility of the region.
Lunatus partners with wide array of healthcare companies and
corresponding brands including Valeant, Mylan, Merz Aesthetics, Omega
Pharma, SoftFil, Opko Lab, Lumenis, BSN Medical, Ferris MFG. Corp. and
IPRAD Laboratories. For more details about Lunatus Marketing and
Consulting please visit www.lunatus-me.com or
email lina@lunatus-me.com.
Cautionary Note Concerning Forward-Looking Statements
This
press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995, including, among
others, statements regarding the capabilities and anticipated utility of
our GPS Cancer, including predicting patient response and resistance to
therapeutics, enabling diagnoses by physicians and accelerating efforts
to bring novel combinations of therapeutic agents to cancer patients, as
well as our contribution to the Cancer 2020 initiative. Forward-looking
statements are subject to numerous risks and uncertainties that could
cause actual results to differ materially from currently anticipated
results. Factors that may cause future results to differ materially from
management’s current expectations include, among other things, that GPS
Cancer may not perform as anticipated, that sufficient physicians may
not adopt GPS Cancer to assist their diagnoses or that healthcare payers
may not provide reimbursement for GPS Cancer as expected. Our business
is subject to numerous additional risks and uncertainties, including,
among others, risks relating to market acceptance of our products; our
ability to successfully launch new products and applications;
competition; our sales, marketing and distribution capabilities; our
planned sales, marketing, and research and development activities;
unanticipated increases in costs or expenses; and risks associated with
international operations. Information on these and additional risks,
uncertainties, and other information affecting our business and
operating results can be found in our existing and future filings with
the Securities and Exchange Commission. These forward-looking statements
speak only as of the date hereof. We disclaim any obligation to update
these forward-looking statements except as may be required by law.
[1]http://grm.grc.net/index.php?pgid=Njk=&wid=NDA=
View source version on businesswire.com: http://www.businesswire.com/news/home/20161205005807/en/
NantWorks
Jen Hodson, 562-397-3639
johodson@nantworks.com
or
Lunatus
Heba
Hani, +971 4 3994755
heba.hani@lunatus-me.com
Source: NantHealth, Inc.
